{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mouth-only+breathing",
    "query": {
      "intervention": "Mouth-only breathing"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 150,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mouth-only+breathing&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T21:24:17.019Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05850494",
      "title": "Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "HFA MDI",
          "type": "DRUG"
        },
        {
          "name": "HFO MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 52,
      "start_date": "2023-05-02",
      "completion_date": "2023-08-21",
      "has_results": true,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 4,
      "location_summary": "North Dartmouth, Massachusetts • St Louis, Missouri • Raleigh, North Carolina + 1 more",
      "locations": [
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05850494"
    },
    {
      "nct_id": "NCT03345407",
      "title": "Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Placebo ELLIPTA",
          "type": "DRUG"
        },
        {
          "name": "Nemiralisib ELLIPTA 50 µg",
          "type": "DRUG"
        },
        {
          "name": "Nemiralisib ELLIPTA 100 µg",
          "type": "DRUG"
        },
        {
          "name": "Nemiralisib ELLIPTA 250 µg",
          "type": "DRUG"
        },
        {
          "name": "Nemiralisib ELLIPTA 500 µg",
          "type": "DRUG"
        },
        {
          "name": "Nemiralisib ELLIPTA 750 µg",
          "type": "DRUG"
        },
        {
          "name": "Albuterol (Salbutamol) MDI or nebules",
          "type": "DRUG"
        },
        {
          "name": "Standard of care therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 943,
      "start_date": "2017-11-28",
      "completion_date": "2019-01-10",
      "has_results": true,
      "last_update_posted_date": "2021-07-14",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 21,
      "location_summary": "Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Adairsville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345407"
    },
    {
      "nct_id": "NCT01844401",
      "title": "Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Albuterol Spiromax®",
          "type": "DRUG"
        },
        {
          "name": "ProAir® HFA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Years to 11 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-04",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2013-11-14",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 1,
      "location_summary": "Costa Mesa, California",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844401"
    },
    {
      "nct_id": "NCT02184767",
      "title": "Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BiPolar"
      ],
      "interventions": [
        {
          "name": "ADASUVE®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-07",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-12",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184767"
    },
    {
      "nct_id": "NCT01899144",
      "title": "Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Albuterol Spiromax",
          "type": "DRUG"
        },
        {
          "name": "ProAir HFA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Years to 11 Years"
      },
      "enrollment_count": 61,
      "start_date": "2013-07",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01899144"
    },
    {
      "nct_id": "NCT02807675",
      "title": "A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "CVT-301, LIP",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-06",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 11,
      "location_summary": "Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807675"
    },
    {
      "nct_id": "NCT07665892",
      "title": "Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety in Asthma Patients"
      ],
      "interventions": [
        {
          "name": "ASY202",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Aspeya, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-05-26",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 3,
      "location_summary": "Glendale, Arizona • Anaheim, California • San Antonio, Texas",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07665892"
    },
    {
      "nct_id": "NCT04645953",
      "title": "Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cyclic Vomiting Syndrome"
      ],
      "interventions": [
        {
          "name": "3mg AZ-010",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "1mg AZ010",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Staccato Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 150,
      "start_date": "2021-02-05",
      "completion_date": "2022-07-26",
      "has_results": true,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 18,
      "location_summary": "Lancaster, California • Los Angeles, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04645953"
    },
    {
      "nct_id": "NCT01651494",
      "title": "Influenza Antiviral DAS-181-F04 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "DAS181",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 9,
      "start_date": "2011-08-12",
      "completion_date": "2012-09-18",
      "has_results": false,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01651494"
    },
    {
      "nct_id": "NCT04461353",
      "title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Acute Respiratory Syndrome Coronavirus 2"
      ],
      "interventions": [
        {
          "name": "Aerolized Hydroxychloroquine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pulmoquine Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-06-25",
      "completion_date": "2020-08-17",
      "has_results": false,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-09-22T21:24:17.019Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04461353"
    }
  ]
}